English (United States)|Italiano (Italia)
English (United States) | Italiano (Italia)
Article details
29 March 2019 - Italfarmaco Group is pleased to announce the marketing of GhemaXan, the first biosimilar of Enoxaparin Sodium developed and produced in Italy

Ghemaxan is indicated for the treatment of deep vein thrombosis and pulmonary embolism (except for PE which may require thrombolytic or surgical therapy), serious conditions that occur by the presence of blood clots, for the prophylaxis of venous thromboembolic disease in different clinical situations (before and after surgery, in case of acute illness and reduced mobility, following a myocardial infarction or by the presence of unstable angina, a disorder caused by poor blood flow to the heart) and to prevent thrombus formation in extra corporeal circulation during haemodialysis.
Italfarmaco produces GhemaXan in the plant of Milan where the highest international quality standards that have been GMP certified by the Italian Drug Agency (AIFA), and by the Food and Drug Administration (the American regulatory agency), since 2004.
The plant is the most important Italian manufacturer of pre-filled syringes and among the few ones existing in Europe with an annual capacity of 80 million pieces.
GhemaXan promotes the environmental sustainability: all the material for Medical and Scientific Information is made from recyclable material and/or from certified sources only.